Dr Guru Subramanian Guru Murthy
Dr Guru Subramanian Guru Murthy
Dr Guru Subramanian Guru Murthy Oncology
MD MS Haematology Medical Oncology (USA) Registered Number –
Milwaukee
Experience – 16 years
Language – English, Hindi, Tamil
Dr. Guru Subramanian Murthy, MD is a health care provider primarily located in Milwaukee, WI, with other offices in MILWAUKEE, WI and Little Rock, AR. He has 16 years of experience. His specialties include Oncology, Internal Medicine. Dr. Murthy is affiliated with Froedtert Lutheran Memorial Hospital.
Education and Training
Tamil Nadu Dr. M.G.R Medical University – Chennai – India – Doctor of Medicine (M.B.B.S) – (2007) University of Arkansas for Medical Sciences – Little Rock – AR – Residency in Internal Medicine – (2013-2015) Medical College of Wisconsin – Milwaukee – Fellowship in Hematology-Oncology – (20152018)
Doctor Say -
“Cancer is a difficult diagnosis for patients and their families. My goal is to help patients with cancer in all possible ways and ease their journey through this difficult path, eventually aiming to beat the cancer”
- Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E.) J Natl Compr Canc Netw. 2020 Feb;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.085079065513 02/06/2020
- Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN.) Oncologist. 2019 Nov;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.085071466837 08/31/2019
- Transformation of a non-secretory neuroendocrine tumor to insulinoma after treatment with Sunitinib: A case report and review of the literature. (Clover T, Abdelkader A, Guru Murthy GS.) J Oncol Pharm Pract. 2019 Sep;25(6):1516-1519 PMID: 30089432 SCOPUS ID: 2-s2.0-85052579205 08/10/2018
- Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. (Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E.) Leuk Lymphoma. 2019 May;60(5):1171-1178 PMID: 30407885 SCOPUS ID: 2-s2.0-85057299329 11/09/2018
- Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D’Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M.) Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833
- Myeloid malignancies after treatment for solid tumours. (Guru Murthy GS, Abedin S.) Best Pract Res Clin Haematol. 2019 Mar;32(1):40-46 PMID: 30927974 SCOPUS ID: 2-s2.0-85062663467 04/01/2019
- Treatment-Free Remission in CML: the US Perspective. (Guru Murthy GS, Atallah E.) Curr Hematol Malig Rep. 2019 Feb;14(1):56-61 PMID: 30645715 SCOPUS ID: 2-s2.0-85060169494 01/16/2019
- Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. (Guru Murthy GS, Pemmaraju N, Atallah E.) Leuk Res. 2018 Oct;73:21-23 PMID: 30189324 SCOPUS ID: 2-s2.0-85052637608 09/07/2018
- Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E.) Leuk Res. 2018 Aug;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018
- Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D’Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M.) Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.085019639994 04/17/2017
- Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? (Jethava Y, Guru Murthy GS, Hamadani M.) Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):47-56 PMID: 28183681 SCOPUS ID: 2-s2.0-85012253423 02/12/2017
- Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. (Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P.) Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):201-206 PMID: 28395812 SCOPUS ID: 2-s2.085017190298 04/12/2017
